References
- Skouby S O. The rationale for a wider range of progestogens. Climacteric 2000; 3(Suppl 2)14–20
- Burkman R T. Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993; 168: 1033–1040
- Hedon B. The evolution of oral contraceptives. Maximizing efficacy, minimizing risks. Acta Obstet Gynecol Scand Suppl 1990; 152: 7–12
- Krauss R M, Burkman R T, Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992; 167: 1177–1184
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38
- Foidart J M. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5(Suppl 3)25–33
- Oelkers W. Drospirenone – a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000; 5(Suppl 3)17–24
- Parsey K S, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105–111
- Oelkers W, Foidart J M, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin – aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–1821
- Gaspard U, Endrikat J, Desager J P, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69: 271–278
- World Health Organization. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use methods. World Health Organization, Geneva 1996
- Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception 1998; 57: 189–201
- Nofer J R, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1–16
- Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71: 409–416
- Jacobs D R, Jr, Mebane I L, Bangdiwala S I, Criqui M H, Tyroler H A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32–47
- Crook D, Godsland I F, Worthington M, Felton C V, Proudler A J, Stevenson J C. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol 1993; 169: 1183–1189
- Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Int J Fertil Menopausal Stud 1995; 40(Suppl 2)98–104
- Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 1998; 58: 83–91
- NIH Consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. J Am Med Assoc 1993; 269: 505–510